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Aims The 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline on high blood pres-
sure (BP) lowered the threshold defining hypertension and BP target in high-risk patients to 130/80 mmHg. Patients
with coronary artery disease and systolic BP 130–139 mmHg or diastolic BP 80–89 mmHg should now receive
medication to achieve this target. We aimed to investigate the relationship between BP and cardiovascular events
in ‘real-life’ patients with coronary artery disease considered as having normal BP until the recent guideline.
...................................................................................................................................................................................................
Methods
and results
Data from 5956 patients with stable coronary artery disease, no history of hypertension or heart failure, and aver-
age BP <140/90 mmHg, enrolled in the CLARIFY registry (November 2009 to June 2010), were analysed.
In a multivariable-adjusted Cox proportional hazards model, after a median follow-up of 5.0 years, diastolic BP 80–
89 mmHg, but not systolic BP 130–139 mmHg, was associated with increased risk of the primary endpoint, a
composite of cardiovascular death, myocardial infarction, or stroke (hazard ratio 2.15, 95% confidence interval
1.22–3.81 vs. 70–79 mmHg and 1.12, 0.64–1.97 vs. 120–129 mmHg). No significant increase in risk for the primary
endpoint was observed for systolic BP <120 mmHg or diastolic BP <70 mmHg.
...................................................................................................................................................................................................
Conclusion In patients with stable coronary artery disease defined as having normal BP according to the 140/90 mmHg thresh-
old, diastolic BP 80–89 mmHg was associated with increased cardiovascular risk, whereas systolic BP 130–
139 mmHg was not, supporting the lower diastolic but not the lower systolic BP hypertension-defining threshold
and treatment target in coronary artery disease.
...................................................................................................................................................................................................
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Introduction
The 2017 American College of Cardiology/American Heart
Association (ACC/AHA) guideline defined hypertension as a blood
pressure (BP) >_130/80 mmHg.1 Following that change, patients with
or at high risk for cardiovascular disease, with systolic BP between
130 and 139 mmHg or diastolic BP between 80 and 89 mmHg, previ-
ously considered as non-hypertensive patients, should now receive
BP-lowering treatment for their newly defined hypertension, with a
target of <130/80 mmHg. In normotensive patients with coronary ar-
tery disease, treated or not with BP-lowering antianginal medication,
the new target is now a BP <130/80 mmHg. This lowered threshold
largely results from the reduced rate of cardiovascular events
observed in the intensive arm of the Systolic Blood Pressure
Intervention Trial (SPRINT) trial.2 However, patients in SPRINT
were carefully followed-up in the setting of a randomized trial, and
unattended automated BP measurements yielded values approxi-
mately 7 mmHg lower than average daytime ambulatory meas-
urement,3 and expected to be approximately 15 mmHg lower than
standard office BP measurement.4,5 Whether translating the results
of SPRINT to real-life patients with standard office BP measurements
will result in a lower cardiovascular event rate is debated.6,7
Furthermore, very few patients in SPRINT had previous coronary ar-
tery disease and were normotensive. The potential impact of the
2017 ACC/AHA guideline on high BP in real-life patients with coron-
ary artery disease requires careful attention.
In the present post hoc analysis, we evaluated the association be-
tween BP level and cardiovascular outcomes, including cardiovascular
mortality, in patients with normal BP (<140/90 mmHg) and stable
coronary artery disease from the CLARIFY registry. These patients
represent the epitome of high-risk patients to whom the lowered
pharmacological intervention threshold in the recent ACC/AHA
guideline applies. Our goal was to determine whether there is an
increased risk associated with systolic and diastolic BP values higher
than 130 and 80 mmHg (vs. 120–129 and 70–79 mmHg, respectively)
in the individuals classified as having normal BP according to the previ-
ous guidelines.
Methods
Study design and participants
The prospective, observational, longitudinal registry of patients with sta-
ble coronary artery disease (CLARIFY; ISRCTN43070564; www.clarify-
registry.com) enrolled 32 703 patients from 45 countries between
November 2009 and June 2010.8,9 Patients were included if they had at
least one of the following: documented myocardial infarction >_3 months
before enrolment, angiographic demonstration of >50% coronary sten-
osis, chest pain with evidence of myocardial ischaemia (at least a stress
electrocardiogram or preferably imaging), or coronary artery bypass graft
or percutaneous coronary intervention >_3 months before enrolment.
Exclusion criteria were hospital admission for cardiovascular reasons
in the past 3 months, planned revascularization, or conditions
compromising the participation or 5-year follow-up (including severe
other cardiovascular disease such as advanced heart failure, severe valve
disease, or history of valve repair or replacement). At baseline and at
each yearly visit for up to 5 years, symptoms, clinical examination, results
of the main clinical and biological tests, treatment, and clinical outcomes
were recorded; office BP was measured in seated subjects after a 5-min
rest, using the same arm throughout the study, with no pre-specified de-
vice. The registry was observational, with no recommendations on clinical
management, and therefore, reflects routine practice. Events were
accepted as reported by physicians and were not adjudicated. However,
all events were source-verified during audits and several measures were
implemented to ensure data quality, including onsite monitoring visits of
100% of the data in 5% of centres selected at random; regular telephone
contact with investigators to limit missing data and loss to follow-up; and
centralized verification of the electronic case report forms for complete-
ness, consistency, and accuracy. The study was conducted in accordance
with the Declaration of Helsinki and local ethical approval was obtained
in all countries. All patients gave written informed consent.
This analysis was restricted to patients without any history of hyper-
tension, and with an average systolic and diastolic BP during follow-up
below 140 and 90 mmHg, respectively (Supplementary material online,
Figure S1). Patients with congestive heart failure (defined as previous
hospitalization for heart failure, or symptoms of heart failure, or a left ven-
tricular ejection fraction <45%) were excluded.
Blood pressure subgroups
Data were analysed using the arithmetic mean of all BP values measured
throughout follow-up, from the baseline visit to the visit before an out-
come event or, in patients without an event, up to the last visit. All analy-
ses were performed for systolic BP and diastolic BP separately. Patients
were categorized into three subgroups for each BP component: systolic
BP <120, 120–129 (reference), and 130–139 mmHg, and diastolic BP
<70, 70–79 (reference), and 80–89 mmHg.
Study outcomes
The primary outcome was the composite of cardiovascular death, myo-
cardial infarction, or stroke. Secondary outcomes were each component
of the primary outcome.
Statistical analysis
Continuous variables are presented as mean ± standard deviation or me-
dian (interquartile range), depending on the distribution of the data; cat-
egorical data are presented as count and percentage. Event rates at
5 years are presented as the Kaplan–Meier estimates with 95% confi-
dence intervals (CIs). Cox proportional hazards models were used to
evaluate the relationship between BP categories and cardiovascular out-
comes. In addition to crude hazard ratios (HRs), adjusted HRs were esti-
mated after adjustment for covariates selected a priori as potential
confounding factors, namely age, sex, geographic region, ethnicity, smok-
ing status, myocardial infarction, percutaneous coronary intervention,
coronary artery bypass grafting, diabetes, low- and high-density lipopro-
tein cholesterol level, body mass index, and glomerular filtration rate [at
baseline, estimated with the chronic kidney disease Epidemiology
Collaboration (CKD-EPI) equation], peripheral artery disease, stroke,
and transient ischaemic attack (any time before enrolment), and baseline
2 E. Vidal-Petiot et al.
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medication (aspirin, statin, angiotensin-converting enzyme inhibitor,
angiotensin-receptor blocker, beta-blocker, calcium channel blocker, and
diuretic). An intermediate adjustment for age and gender was also
performed.
Interactions between average systolic or diastolic BP and covariate age
(>75 vs. <_75 years), diabetes, and chronic kidney disease (defined as esti-
mated glomerular filtration rate <60 mL/min/1.73 m2, using the CKD-EPI
equation) at baseline were tested. In addition, interactions between sys-
tolic and diastolic BP were also tested.
Statistical analyses were performed using SAS (version 9.3). A P-value
<0.05 was used to signify statistical significance using two-sided testing,
with no correction for multiple comparisons.
Role of the funding source
The CLARIFY registry is supported by Servier. The sponsor had no role
in the study design or in data analysis and interpretation, or in the decision
to submit the manuscript for publication, but assisted with the set-up,
data collection, and management of the study in each country. The corre-
sponding author had full access to all the data in the study and the final re-
sponsibility for the decision to submit for publication.
Results
A total of 5956 patients with stable coronary artery disease, without
any history of hypertension, and with average BP <140/90 mmHg,
were included in the analysis. Baseline characteristics of the patients
are given for total population and by average follow-up systolic BP
subgroups in Table 1, and by average follow-up diastolic BP subgroups
in Table 2. Baseline medications are reported in Supplementary ma-
terial online, Tables S1 and S2, and the number of patients in each sub-
group of systolic BP, cross-classified with subgroups of diastolic BP, is
reported in Supplementary material online, Table S3. Mean age at
baseline was 61.0 ± 10.8 years, 4973 (83%) were men, and 1031
(17%) had diabetes. Mean average systolic and diastolic BPs were
122.7 ± 12.4 and 74.1± 9.8 mmHg, respectively. Compared with
patients with systolic BP 130–139 mmHg, those with a lower systolic
BP tended to be younger, leaner, less likely to have diabetes, and to
have lower total cholesterol and triglyceride levels. Compared with
patients with diastolic BP 80–89 mmHg, those with a lower diastolic
BP tended to be older, leaner, more likely to be female, to have dia-
betes, and tended to have lower total cholesterol and triglyceride
levels.
After a median follow-up of 5.0 years (IQR 4.2–5.1), 145 patients
(2.7%, 95% CI 2.3–3.2) met the primary composite outcome.
Cardiovascular death occurred in 114 (2.1%, 95% CI 1.8–2.6)
patients, myocardial infarction (fatal or not) in 48 patients (0.9%, 95%
CI 0.7–1.2), and stroke (fatal or not) in 29 (0.5%, 95% CI 0.4–0.7)
patients.
Kaplan–Meier crude event rates and multivariable adjusted HRs
are reported in the Take home figure for the primary outcome, and
in Table 3 for systolic BP subgroups and Table 4 for diastolic BP
subgroups, for secondary outcomes. Age and sex-adjusted HRs
are reported along unadjusted and fully adjusted HRs in
Supplementary material online, Tables S4 and S5. Compared with
the reference group for systolic BP (120–129 mmHg), the risk for
the primary outcome was not increased in the 130–139 mmHg
subgroup, with an adjusted HR for the primary outcome of 1.12
(95% CI 0.64–1.97). There was no evidence of an increased risk in
the <120 mmHg systolic BP either, with an adjusted HR of 1.16
(95% CI 0.65–2.05). Similar results were observed for each separ-
ate component of the primary endpoint.
In contrast, compared with the reference group of patients with a
diastolic BP of 70–79 mmHg, the adjusted HR for the primary out-
come was 2.15 (95% CI 1.22–3.81) for diastolic BP 80–89 mmHg.
A significant increase in the risk for cardiovascular death or stroke
was also observed for diastolic BP 80–89 mmHg compared with 70–
79 mmHg. There was no statistical evidence for increased risks for
the primary outcome or secondary outcomes in the lowest diastolic
BP subgroup (<70 mmHg) after adjustment for covariates.
Interaction analyses are given in the Supplementary material on-
line, Tables S6 to S8. No significant effect-modification of age, diabetes,
or chronic kidney disease at baseline was detected on the association
between systolic BP or diastolic BP and primary or secondary out-
comes. Interactions between systolic and diastolic BP were non-
significant, with P-values of 0.33, 0.39, 0.20, and 0.87 for the primary
endpoint, cardiovascular death, myocardial infarction, and stroke re-
spectively, suggesting that the increased risk observed for a diastolic
BP between 80 and 89 mmHg compared with 70–79 mmHg
remained across all systolic BP subgroups.
Discussion
This observational study conducted in a large population of patients
with coronary artery disease, no history of hypertension, and average
follow-up BP <140/90 mmHg, treated according to standard care,
showed that a systolic BP between 130 and 139 mmHg was not asso-
ciated with an increased cardiovascular risk compared with a systolic
BP between 120 and 129 mmHg. However, the risk associated with a
diastolic BP between 80 and 89 mmHg was significantly greater than
that of a diastolic BP between 70 and 79 mmHg. Although observa-
tional, our data do not support initiation of BP-lowering therapy (or
more-intensive treatment in those receiving antianginal BP-lowering
drugs) in patients newly defined as hypertensive according to the
2017 AHA/ACC guideline because of a systolic BP between 130 and
139 mmHg.
The CLARIFY registry provides a unique population of patients
with stable coronary artery disease, including nearly 6000 normoten-
sive patients, as defined from the 140/90 mmHg threshold, a third of
whom were in the 130-139 mmHg range, to study the relationship
between BP and cardiovascular events. Indeed, evidence supporting
the new definition of hypertension and lower targets in patients with
coronary artery disease is lacking. BP-intervention trials included a
large majority of hypertensive patients, and very few trials until
SPRINT lowered systolic BP below 130 mmHg, with overall no sig-
nificant reduction in cardiovascular events except stroke below this
threshold.10 In the Prevention of Events with Angiotensin Converting
Enzyme Inhibition (PEACE) trial,11 which tested trandolapril vs. pla-
cebo in patients with stable coronary artery disease and normal or
slightly reduced left ventricular function (more than half of whom
were normotensive), patients in the treatment arm reached a mean
BP below 130 mmHg, which was not associated with a reduced rate
of cardiovascular events. However, the BP difference between the
two groups was only 3 mmHg. In the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) and SPRINT trials,
Potential impact of the 2017 ACC/AHA guideline on high blood pressure 3
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which randomized patients to an intensive (<120 mmHg) or a stand-
ard (<140 mmHg) treatment target, inclusion criteria did not man-
date hypertension (only a systolic BP >_130 mmHg).2,12 In both trials,
approximately 10% of the patients did not receive BP-lowering drugs,
and as some patients may have had systolic BP between 130 and
139 mmHg, only a small fraction of the populations were normoten-
sive according to the 140/90 mmHg threshold. In addition, 33% of the
ACCORD, and 17% of the SPRINT populations had a previous car-
diovascular event, which leaves very few patients with normotension
and coronary artery disease. Overall, even though the combined ana-
lysis of these trials favoured intensive treatment,13 no clear conclu-
sion can be drawn on intensive BP-lowering in normotensive patients
with coronary artery disease. Noteworthy, in SPRINT, mean age was
7 years older than in CLARIFY, and patients with diabetes or previous
stroke were excluded, also limiting the comparison between these
two studies. In the Secondary Prevention of Small Subcortical
Strokes (SPS3) BP target trial, in which the intensive target systolic BP
was <130 mmHg in patients with previous stroke, there was no sig-
nificant reduction in recurrent stroke, myocardial infarction, or death,
but only 25% were normotensive, and 11% had previous coronary
artery disease.14 The randomized Heart Outcomes Prevention
Evaluation (HOPE)-3 trial included a large proportion of normoten-
sive patients (62%) and showed no benefit associated with the can-
desartan–hydrochlorothiazide therapy despite achieved BP below
130 mmHg in the treatment arm; however, this trial included
intermediate-risk patients with no cardiovascular disease at
baseline.15
The higher risk observed for diastolic BP of 80–89 mmHg com-
pared with 70–79 mmHg is in line with meta-analyses of more- vs.
less-intensive BP-lowering trials, even those conducted before
SPRINT.16,17 However, no such trial with a mean achieved BP in both
groups across the 80 mmHg threshold was conducted in patients
with coronary artery disease. In a recent post hoc analysis from the
Ongoing Telmisartan Alone and in Combination with Ramipril
Global Endpoint Trial (ONTARGET) and Telmisartan Randomized
AssessmeNt Study in ACE iNtolerant participants with cardiovascu-
lar Disease TRANSCEND patients with achieved systolic BP be-
tween 120 and 139 mmHg, a diastolic BP of 80–89 mmHg compared
with 70–79 mmHg, was associated with a higher risk for stroke and
hospitalization for heart failure.18
Although there are observational data on optimal BP targets in
hypertensive patients with coronary artery disease,19,20 no observa-
tional study was conducted specifically in normotensive patients with
coronary artery disease. However, in the post hoc analysis of the
Treating to New Targets (TNT) trial,21 which included 10 001
patients with coronary artery disease, 46% of whom were normoten-
sive at baseline, the relationship between systolic or diastolic BP and
a composite endpoint of cardiovascular events showed a J-curve,
....................................................................................................................................................................................................................
Table 1 Baseline characteristics for the total population and for each subgroup of systolic blood pressure
n Total population
(n5 5956)
<120 mmHg
(n51779)
120–129 mmHg
(n5 2532)
130–139 mmHg
(n51645)
P-value
Age (years) 5955 61.0 (10.8) 58.7 (11.0) 61.1 (10.5) 63.4 (10.6) <0.0001
Men 5955 4973 (83%) 1474 (82%) 2139 (84%) 1361 (83%) 0.22
Body mass index (kg/m2) 5949 26.2 (24.09–28.71) 25.5 (23.53–27.78) 26.3 (24.17–28.95) 26.8 (24.62–29.28) <0.0001
Diabetes 5956 1031 (17%) 279 (16%) 425 (17%) 327 (20%) 0.0034
Smoking status 5956 — — — — 0.13
Current — 895 (15%) 292 (16%) 378 (15%) 225 (14%) —
Former — 2986 (50%) 889 (49%) 1283 (51%) 815 (50%) —
Never — 2075 (35%) 599 (33%) 871 (34%) 605 (37%) —
Systolic blood pressure (mmHg) 5954 122.7 (12.4) 111.8 (9.8) 123.7 (8.9) 132.7 (10.0) <0.0001
Diastolic blood pressure (mmHg) 5954 74.1 (8.5) 69.8 (8.4) 75.1 (7.7) 77.3 (8.0) <0.0001
Heart rate (b.p.m.) 4098 65.1 (10.6) 64.5 (10.7) 65.0 (10.4) 66.1 (10.9) 0.0007
Myocardial infarction 5956 3535 (59%) 1123 (63%) 1498 (59%) 914 (56%) <0.0001
Percutaneous coronary intervention 5955 3991 (67%) 1223 (69%) 1720 (68%) 1048 (64%) 0.0031
Coronary artery bypass graft surgery 5956 1071 (18%) 286 (16%) 451 (18%) 334 (20%) 0.0054
Transient ischaemic attack 5955 91 (2%) 33 (2%) 37 (1%) 21 (1%) 0.36
Stroke 5956 89 (1%) 30 (2%) 38 (2%) 21 (1%) 0.61
Left ventricular ejection fraction (%) 3671 60.1 (7.8) 59.3 (7.9) 60.2 (7.9) 60.7 (7.6) 0.0003
HbA1c (%) 1264 6.5 (1.2) 6.4 (1.3) 6.5 (1.2) 6.6 (1.3) 0.0450
Creatinine (mmol/L) 4459 86 (74–97) 85 (74–96) 86 (74–97) 86 (73–97) 0.40
Total cholesterol (mmol/L) 4753 4.2 (3.6–4.9) 4.1 (3.5–4.8) 4.2 (3.6–4.9) 4.3 (3.7–4.9) 0.0001
HDL cholesterol (mmol/L) 4440 1.14 (0.98–1.38) 1.13 (0.96–1.35) 1.16 (0.99–1.38) 1.17 (0.99–1.40) 0.076
LDL cholesterol (mmol/L) 4239 2.33 (1.87–2.86) 2.30 (1.82–2.81) 2.34 (1.89–2.86) 2.36 (1.90–2.91) 0.0414
Fasting triglycerides (mmol/L) 4452 1.30 (0.95–1.79) 1.20 (0.90–1.68) 1.31 (0.97–1.80) 1.34 (0.97–1.87) <0.0001
Data are n (%) for categorical data and mean (SD) or median (IQR) for continuous data, depending on the distribution of the data. Some percentages do not add up to 100%
because of rounding.
HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NYHA, New York Heart Association.
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with nadir values of 146 and 81 mmHg, respectively. There was no
interaction with hypertension, suggesting similar results in normoten-
sive patients. These results concur with the present observations,
showing a benefit of BP reduction down to a threshold lower than
the standard 90 mmHg for diastolic BP but not lower than the
140 mmHg threshold for systolic BP.
The rationale for more-intensive treatment in high-risk patients is
the greater absolute risk reduction as baseline cardiovascular risk
increases.22–24 Patients with established coronary artery disease are
clearly one such high-risk group. However, the benefits of more-
intensive BP control have not been consistently observed in patients
with coronary artery disease,10 potentially because low BP—particu-
larly low diastolic BP—may also be deleterious in this population, as
described in several observational studies.20,25–27
Of note, the results from the present study are consistent with
those obtained in treated hypertensive patients from the same regis-
try, in which patients with stable coronary artery disease and treated
for hypertension, with an on-treatment systolic BP between 130 and
139 mmHg, did not have an increased risk compared with patients
with systolic BP 120–129 mmHg; in contrast, a marked and progres-
sive increase was observed for a systolic BP value >140 mmHg, and
for diastolic BP values >80 mmHg, compared with patients with
diastolic BP of 70–79 mmHg. Overall, these results from the
CLARIFY registry do not support the lower systolic BP threshold of
the 2017 ACC/AHA guideline on high BP in patients with coronary
artery disease, whereas the expected cost of implementation of these
recommendations would be major.28–30
Interestingly, in this population of normotensive patients, no signifi-
cantly increased risk of cardiovascular events was observed in
patients in the lowest BP subgroups, unlike what was previously
observed in treated hypertensive patients of the same registry.20 We
cannot rule out that the present study may be underpowered to
highlight a so-called ‘J-curve’ phenomenon. However, another poten-
tial explanation for this discrepancy is that during hypertension,
autoregulation is shifted rightwards, to a higher pressure range, and
patients tend to have increased left ventricular mass, both of which
may contribute to the increased risk of adverse events associated
with low BP values.31,32 Therefore, the inflection of the so-called
‘J-curve’ may occur at lower BP values in normotensive than in hyper-
tensive patients.
Our study has certain limitations. First, CLARIFY is an observation-
al registry, and is therefore, prone to confounding, and possibly to
less accurate outcome identification than in randomized controlled
trials; only dedicated randomized controlled trials in patients with
......................................................................................................................................................................................................................
Table 2 Baseline characteristics for each subgroup of diastolic blood pressure
n <70 mmHg
(n51200)
70–79 mmHg
(n53523)
80–89 mmHg
(n5 1233)
P-value
Age (years) 5955 62.9 (11.1) 61.2 (10.7) 58.8 (10.5) <0.0001
Men 5955 942 (79%) 2984 (85%) 1047 (85%) <0.0001
Body mass index (kg/m2) 5949 25.6 (23.42–28.17) 26.2 (24.159–28.720) 26.8 (24.676–29.055) <0.0001
Diabetes 5956 238 (20%) 609 (17%) 184 (15%) 0.0060
Smoking status 5956 — — — 0.0268
Current — 158 (13%) 524 (15%) 213 (17%) —
Former — 599 (50%) 1798 (51%) 589 (48%) —
Never — 443 (37%) 1201 (34%) 431 (35%) —
Systolic blood pressure (mmHg) 5954 116.2 (13.5) 123.0 (11.6) 128.0 (10.4) <0.0001
Diastolic blood pressure (mmHg) 5954 64.9 (7.0) 74.5 (6.6) 82.0 (5.8) <0.0001
Heart rate (b.p.m.) 4098 63.6 (10.4) 65.0 (10.6) 66.6 (10.8) <0.0001
Myocardial infarction 5956 723 (60%) 2089 (59%) 723 (59%) 0.71
Percutaneous coronary intervention 5955 776 (65%) 2360 (67%) 855 (69%) 0.0494
Coronary artery bypass graft surgery 5956 257 (21%) 632 (18%) 182 (15%) 0.0001
Transient ischaemic attack 5955 23 (2%) 51 (1%) 17 (1%) 0.46
Stroke 5956 18 (2%) 51 (1%) 20 (2%) 0.91
Left ventricular ejection fraction (%) 3671 59.2 (7.9) 60.2 (7.8) 60.3 (7.8) 0.0075
HbA1c (%) 1264 6.7 (1.3) 6.4 (1.2) 6.5 (1.3) 0.0019
Creatinine (mmol/L) 4459 86 (74–97) 86 (74–97) 84 (72–97) 0.22
Total cholesterol (mmol/L) 4753 4.0 (3.5–4.7) 4.2 (3.6–4.8) 4.4 (3.8–5.1) <0.0001
HDL cholesterol (mmol/L) 4440 1.13 (0.97–1.38) 1.16 (0.97–1.38) 1.14 (0.99–1.35) 0.76
LDL cholesterol (mmol/L) 4239 2.20 (1.77–2.70) 2.34 (1.90–2.83) 2.47 (1.98–3.07) <0.0001
Fasting triglycerides (mmol/L) 4452 1.21 (0.90–1.62) 1.30 (0.95–1.80) 1.40 (1.00–1.89) <0.0001
Data are n (%) for categorical data and mean (SD) or median (IQR) for continuous data, depending on the distribution of the data. Some percentages do not add up to 100%
because of rounding.
HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NYHA, New York Heart Association.
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..coronary artery disease would provide a definite answer on the opti-
mal BP target in this population. Second, patients underwent casual
office BP measurement, which is not as accurate and standardized as
the conditions of BP measurement in randomized trials, and especial-
ly not as stringent as in the SPRINT trial, where unattended measure-
ment ensured minimizing any white-coat effect. However, routine
clinical practice worldwide relies on casual office BP measurements;
these ‘real-life’ observations in a large number of patients should also
be taken into consideration when trying to translate scientific data
into clinical practice recommendations. In addition, owing to a low
number of patients, we were not able to analyse the consequences of
very low BP values: <110 mmHg for systolic BP and <60 mmHg for
diastolic BP. This could be of importance, as in patients with cardio-
vascular disease and increased arterial stiffness, targeting a systolic BP
<130 mmHg may not infrequently be at the cost of reaching low sys-
tolic and diastolic BP values, the potential harm of which requires fur-
ther careful consideration and dedicated studies. Furthermore,
although our population was selected using the combination of ab-
sence of history of hypertension according to the clinician, and an
average follow-up BP <140/90 mmHg, it is likely that some patients
would have a clinical diagnosis of hypertension if antianginal drugs
were withdrawn. However, in the event of routine clinical implemen-
tation of the guidelines recommending a lower threshold for antihy-
pertensive treatment, the patients of the present study are those
Take home ﬁgure Kaplan-Meier estimated crude event rates, HRs (95% confidence interval), and forest plot of adjusted HRs (95% confidence
interval) of the primary outcome (cardiovascular death, myocardial infarction, or stroke). The analyses were adjusted for age, sex, geographic region,
ethnicity, smoking status, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, diabetes, low- and high-density
lipoprotein cholesterol level, body mass index, glomerular filtration rate, peripheral artery disease, stroke, transient ischaemic attack, and baseline
medication (aspirin, statin, angiotensin-converting enzyme inhibitor, angiotensin-receptor blocker, beta-blocker, calcium channel blocker, and
diuretic).
...............................................................................................................................
....................................................................................................................................................................................................................
Table 3 Event rates and unadjusted and adjusteda hazard ratios for systolic BP subgroups (secondary outcomes)
Outcomes Parameters Systolic BP subgroup
<120 mmHg 120–129 mmHg 130–139 mmHg P-value
Cardiovascular death n/N 33/1779 43/2532 38/1645
Crude event rate (%) 2.0 (1.4–2.9) 1.9 (1.4–2.5) 2.7 (1.9–3.7) 0.52
Unadjusted HR 1.09 (0.69–1.72) 1.00 (–) 1.36 (0.88–2.11) 0.36
Adjusted HR 1.20 (0.63–2.30) 1.00 (–) 1.19 (0.64–2.20) 0.81
Myocardial infarction n/N 11/1779 20/2532 17/1645
Crude event rate (%) 0.7 (0.4–1.3) 0.9 (0.6–1.4) 1.1 (0.7–1.8) 0.58
Unadjusted HR 0.78 (0.37–1.63) 1.00 (–) 1.31 (0.69–2.50) 0.40
Adjusted HR 1.16 (0.40–3.39) 1.00 (–) 1.70 (0.62–4.66) 0.57
Stroke n/N 9/1779 13/2532 7/1645
Crude event rate (%) 0.5 (0.2–1.0) 0.6 (0.3–1.0) 0.5 (0.2–1.0) 0.98
Unadjusted HR 0.99 (0.42–2.30) 1.00 (–) 0.83 (0.33–2.08) 0.92
Adjusted HR 1.67 (0.56–4.99) 1.00 (–) 0.85 (0.24–3.01) 0.52
Event rates (95% CI) are indicated as the Kaplan–Meier estimates.
BP, blood pressure; HR, hazard ratio; n/N, number of events/number of patients.
aAdjusted for age, sex, geographic region, ethnicity, smoking status, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, diabetes, low-
and high-density lipoprotein cholesterol level, body mass index, glomerular filtration rate, peripheral artery disease, stroke, transient ischaemic attack, and baseline medication
(aspirin, statin, angiotensin-converting enzyme inhibitor, angiotensin-receptor blocker, beta-blocker, calcium channel blocker, diuretic).
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..whom clinicians would consider eligible for this new recommenda-
tion. Finally, our results were obtained in a population of normoten-
sive patients with stable coronary artery disease (CAD), with a fairly
small proportion of patients with diabetes (17%), and cannot be
extrapolated to normotensive patients at higher cardiovascular risk,
or unstable CAD.
Conclusion
In conclusion, this large international cohort study shows that in
normotensive patients with stable coronary artery disease, the cardio-
vascular risk associated with an average systolic BP of 130–139 mmHg
is not higher than that of patients with a systolic BP of 120–
129 mmHg, and therefore does not support initiation of BP-lowering
therapy in this population. Conversely, patients with diastolic BP be-
tween 80 and 89 mmHg (and systolic BP <140 mmHg) have a signifi-
cantly increased risk compared with patients with a diastolic BP of 70–
79 mmHg, even after multiple adjustments for potential confounders.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Table 4 Event rates and unadjusted and adjusteda hazard ratios for diastolic BP subgroups (secondary outcomes)
Outcomes Parameters Diastolic BP subgroup
<70 mmHg 70–79 mmHg 80–89 mmHg P-value
Cardiovascular death n/N 33/1200 52/3523 29/1233
Crude event rate (%) 3.0 (2.1–4.2) 1.7 (1.3–2.2) 2.7 (1.9–3.8) 0.0179
Unadjusted HR 1.87 (1.25–2.90) 1.00 (–) 1.61 (1.02–2.53) 0.01
Adjusted HR 1.04 (0.54–1.98) 1.00 (–) 2.14 (1.11–4.13) 0.07
Myocardial infarction n/N 14/1200 23/3523 11/1233
Crude event rate (%) 1.3 (0.8–2.2) 0.7 (0.5–1.1) 1.0 (0.6–1.9) 0.35
Unadjusted HR 1.79 (0.92–3.48) 1.00 (–) 1.37 (0.67–2.81) 0.22
Adjusted HR 0.84 (0.30–2.38) 1.00 (–) 1.35 (0.43–4.22) 0.78
Stroke n/N 7/1200 12/3523 10/1233
Crude event rate (%) 0.5 (0.2–1.2) 0.4 (0.2–0.6) 0.9 (0.5–1.7) 0.18
Unadjusted HR 1.71 (0.67–4.35) 1.00 (–) 2.39 (1.03–5.52) 0.12
Adjusted HR 1.28 (0.34–4.74) 1.00 (–) 3.67 (1.24–10.86) 0.054
Event rates (95% CI) are indicated as the Kaplan–Meier estimates.
BP, blood pressure; HR, hazard ratio; n/N, number of events/number of patients.
aAdjusted for age, sex, geographic region, ethnicity, smoking status, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, diabetes, low-
and high-density lipoprotein cholesterol level, body mass index, glomerular filtration rate, peripheral artery disease, stroke, transient ischaemic attack, and baseline medication
(aspirin, statin, angiotensin-converting enzyme inhibitor, angiotensin-receptor blocker, beta-blocker, calcium channel blocker, diuretic).
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